Suchergebnisse - "Dvorkin, Mikhail"

PubPharm (4)

1

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer : The ASTRUM-005 Randomized Clinical Trial

enthalten in: JAMA | 2022

von Cheng, Y. | Han, L. | Wu, L. | +106

CommentIn: JAMA. 2022 Sep 27;328(12):1205-1207. - PMID 36166047

2

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab : Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2021

von Syrigos, K. | Abert, I. | Andric, Z. | +13

3

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : updated results from a randomised, controlled, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Goldman, J. | Dvorkin, M. | Chen, Y. | +123

CommentIn: Lancet Oncol. 2021 Mar;22(3):e83. - PMID 33662291

4

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : a randomised, controlled, open-label, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Paz-Ares, L. | Dvorkin, M. | Chen, Y. | +122

CommentIn: Lancet. 2019 Nov 23;394(10212):1884-1885. - PMID 31590987

1
[1]